Enlivex Therapeutics Ltd. - Ordinary Shares (ENLV) Covered Calls
You can sell covered calls on Enlivex Therapeutics Ltd. - Ordinary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ENLV (prices last updated Fri 4:16 PM ET):
| Enlivex Therapeutics Ltd. - Ordinary Shares (ENLV) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 1.44 | -0.01 | 1.44 | 1.53 | 58K | - | 0.0 |
| Covered Calls For Enlivex Therapeutics Ltd. - Ordinary Shares (ENLV) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| May 17 | 2.5 | 0.00 | 1.53 | 0.0% | 0.0% | |
| Jun 21 | 2.5 | 0.05 | 1.48 | 3.4% | 21.8% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate, which is in Phase IIb clinical trial in patients with severe sepsis; that is in investigator-initiated Phase II clinical trial for the treatment of COVID-19 patients in severe and critical conditions; and which is in Phase IIa clinical trial for the prevention of Graft Versus Host Disease in allogeneic hematopoietic stem cell transplants (HSCT) patients. The company is also developing Allocetra for the prevention of complications associated with bone marrow transplantations and/or HSCT, and acute multiple organ failure. It also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
| Top 10 Open Interest For May 17 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | IWM covered calls | 6. | EEM covered calls | 1. | WOLF covered calls | |
| 2. | HYG covered calls | 7. | KWEB covered calls | 2. | FSLY covered calls | |
| 3. | QQQ covered calls | 8. | SLV covered calls | 3. | ENVX covered calls | |
| 4. | SPY covered calls | 9. | TSLA covered calls | 4. | NOVA covered calls | |
| 5. | FXI covered calls | 10. | NVDA covered calls | 5. | COIN covered calls | |
Want more examples? ENLC Covered Calls | ENPH Covered Calls
